Adjuvant camrelizumab for hepatocellular carcinoma patients with high risk of recurrence after curative hepatectomy: a retrospective multicenter study
Adjuvant camrelizumab may improve the prognosis of patients with HCC at high risk of recurrence after curative hepatectomy. Combination therapy with TKIs may be unnecessary.
Authors
- K E CHEN
- Ze Su (ORCID: https://orcid.org/0009-0000-1360-0783)
- Da-Long Yang (ORCID: https://orcid.org/0000-0002-2931-1166)
- Xiunan Wang (ORCID: https://orcid.org/0000-0003-4070-4101)
- Fuquan Yang (ORCID: https://orcid.org/0000-0002-2841-5342)
- Shaoping Liu
- Ye-Hao Zou
- Lei-Po Lin
- Ning Peng
- Min Luo
- Zhong-Yue Mo
- Jia-Yong Su
- Xiao-Feng Dong
- Kun-Hua Deng
- Li-Chun Zhou
- Jian-Hong Zhong
- Wei-Ming Liang
- Liang Ma
- Po-Hua Ye
Institutions
- Guangxi Medical University (CN)
- Guigang City People's Hospital (CN)
- The People's Hospital of Guangxi Zhuang Autonomous Region (CN)
- First Affiliated Hospital of GuangXi Medical University (CN)
- The Second Nanning People's Hospital (CN)
- First People's Hospital of Nanning (CN)
- Yulin University (CN)
Publication Details
- Journal
- European Journal of Gastroenterology & Hepatology
- Published
- 2026-03-02
- DOI
- https://doi.org/10.1097/meg.0000000000003158
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00